Parkinson's Disease Treatments Market Size, Share & Trends Analysis Report By Type (Dopamine Agonists, Levodopa, Glutamate Antagonist, Apomorphine, COMT Inhibitors Anticholinergics, MAO-B Inhibitors, Other Drugs), By Application (Hospitals, Healthcare Institutes, Others), By Region, And Segment Forecasts, 2023 – 2031

Category : Pharmaceuticals and Healthcare
Pages : 119

Choose License Type

Get Free Sample

Check Discount

Table Of Content

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Parkinsons Disease Treatments Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Parkinsons Disease Treatments Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Parkinsons Disease Treatments Market, By Type
1. Introduction
  1. Market Size and Forecast, By Type
2. Dopamine Agonists
  1. Market Size and Forecast, By Region
3. Levodopa
  1. Market Size and Forecast, By Region
4. Glutamate Antagonist
  1. Market Size and Forecast, By Region
5. Apomorphine
  1. Market Size and Forecast, By Region
6. COMT Inhibitors Anticholinergics
  1. Market Size and Forecast, By Region
7. MAO-B Inhibitors
  1. Market Size and Forecast, By Region
8. Other Drugs
  1. Market Size and Forecast, By Region
Parkinsons Disease Treatments Market, By Application
1. Introduction
  1. Market Size and Forecast, By Application
2. Hospitals
  1. Market Size and Forecast, By Region
3. Healthcare Institutes
  1. Market Size and Forecast, By Region
4. Others
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  2. U.S.
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  2. U.K.
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  2. China
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  3. Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  2. UAE
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  2. Brazil
    1. By Type
      1. Dopamine Agonists
      2. Levodopa
      3. Glutamate Antagonist
      4. Apomorphine
      5. COMT Inhibitors Anticholinergics
      6. MAO-B Inhibitors
      7. Other Drugs
    2. By Application
      1. Hospitals
      2. Healthcare Institutes
      3. Others
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2023
1. Introduction
2. Parkinsons Disease Treatments Market Share Analysis, 2023 (%)
  1. Market Share Analysis, 2023
  2. Competition Ranking, 2023
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. GSK
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Merck
3. Novartis
4. Teva
5. Boehringer Ingelheim
6. Impax
7. Abbvie
8. Valeant Pharmaceuticals
9. Lundbeck
10. Sun Pharma
11. Wockhardt
12. Acadia
13. UCB

Check Discount Request a free sample

Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Single User - $ 3800

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.

Enterprise User - $4800

Testimonials

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
Marketing Manager at a pharma company in Belgium